Thalidomide shows promise for recurrent ovarian treatmentFebruary 28th, 2008 - 12:23 pm ICT by admin
Washington, Feb 28 (ANI): Thalidomide, a drug banned in the 1950s for causing birth defects, is showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a new study.
In the study, led by Levi Downs, Jr., M.D., assistant professor and a researcher of gynecologic oncology at the University of Minnesota Medical School and Cancer Center, Phase II clinical trial was randomized.
For some women, ovarian cancer has become a chronic disease. The standard chemotherapy regimens can put recurrent cancer in remission, often more than once. However, when the cancer resists the standard treatments, we need new options for treatment, Downs said.
The study compared the effectiveness and safety of the combination of thalidomide and topotecan, a chemotherapy often used for ovarian cancer, versus topotecan alone for treatment of recurrent epithelial ovarian cancer in patients who had received prior treatment.
Epithelial ovarian cancer is a disease in which cancer cells form in the tissue that covers the ovary.
In the study, 75 women were evaluated who were randomly assigned to receive either the combination of thalidomide and topotecan or only topotecan.
We found that patients who received topotecan plus thalidomide showed an overall response rate of 47 percent compared to 21 percent response in patients who received only topotecan. In patients receiving topotecan plus thalidomide, 30 percent achieved a complete response, meaning the cancer went away, compared to 18 percent for patients only getting topotecan, Downs said.
Furthermore, patients getting topotecan plus thalidomide had a longer cancer-free period after treatment than those receiving topotecan alone. What all of this means is that while thalidomide may not cure ovarian cancer, it may broaden the treatment options available to physicians and provide more hope to women diagnosed with the cancer, Downs added.
The study has been published in the journal Cancer. (ANI)
- New drug shows promise against platinum resistant ovarian cancer - Oct 10, 2010
- Cancer drug could combat ovarian tumours - Oct 12, 2010
- Expert casts doubts on results of ovarian cancer study - Oct 16, 2010
- Chemo-radiotherapy prevents bladder cancer recurrences - Oct 26, 2010
- Drug discovery combats ovarian cancer - Jun 05, 2011
- How ovarian cancer resists chemotherapy - Mar 03, 2011
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- TTF therapy, chemo combo 'increase survival for lung cancer patients' - Oct 11, 2010
- Potential new target for treatment of ovarian cancer identified - Aug 17, 2010
- Vaccine extends life of brain cancer patients - Apr 19, 2012
- New procedure busts deadly brain tumour cells - Feb 06, 2012
- Bone drug may help fight breast cancer - Jun 03, 2010
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- Treatment of pregnant breast cancer patients shouldn't be delayed - Dec 13, 2010
- New discovery may help in the fight against ovarian cancer - Feb 04, 2011
Tags: assistant professor, birth defects, cancer cells, cancer center, center phase, chemotherapy, chronic disease, clinical trial, epithelial ovarian cancer, free period, minnesota medical school, ovarian cancer, ovary, recurrent cancer, recurrent ovarian cancer, response rate, topotecan, treatment options, university of minnesota medical, university of minnesota medical school